Utah Doctor's DEA License Revoked for Risky Opioid Prescriptions
Published Date: 1/15/2026
Notice
Summary
Dr. Jason Vanshaar from Utah had his DEA license suspended and is facing revocation because he prescribed lots of strong drugs in unsafe ways, risking public health. This affects him directly and means he can’t legally prescribe controlled substances anymore. The decision is final as of early 2026, stopping him from getting new DEA registrations and protecting patients from harm.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked
The Drug Enforcement Administration revoked Jason VanShaar, M.D.'s DEA Certificate of Registration No. FV2721694 and denied his pending application No. W24166810C. The Order also denies any other pending applications he submitted in Utah or Arizona; the revocation is effective February 17, 2026.
Immediate Suspension Began May 28, 2025
On May 28, 2025 the DEA issued an Order to Show Cause and an Immediate Suspension of Registration for Jason VanShaar, M.D., suspending his DEA registration (No. FV2721694) pending final agency action. That suspension removed his ability to hold an active DEA registration beginning with the May 28, 2025 suspension.
Findings: Dangerous Prescribing; Patient Protection
The DEA found that from at least February 2021 to at least March 2025 the registrant issued at least 288 prescriptions for Schedule II–IV controlled substances to four patients, including many 'Holy Trinity' opioid/benzodiazepine/carisoprodol combinations that increase overdose risk. The agency stated the action (suspension and revocation) was taken to protect the public health and safety.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2026-00626 — Walter Walters, M.D.; Decision and Order
Dr. Walter Walters from Indiana lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his certificate. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and patients.
Next: 2026-00629 — Pine Pharmacy; Decision and Order
Pine Pharmacy in Florida lost its DEA registration because it filled risky prescriptions without proper checks and let unauthorized people order controlled drugs. This means Pine Pharmacy can no longer legally handle certain medicines, protecting public safety. The change is effective immediately, so patients and the pharmacy must adjust fast.